Advancement in chemotherapy and molecular targeted therapy of advanced gastric cancers
10.3760/cma.j.issn.1008-1372.2016.01.007
- VernacularTitle:晚期胃癌化疗及分子靶向治疗研究进展
- Author:
Fang WANG
;
Jiang LIU
;
Jian LUO
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms/TH;
Review
- From:
Journal of Chinese Physician
2016;18(1):18-21,25
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapy is still the main treatment in advanced gastric cancer by now,but no standard approach has been adopted.Chemotherapy can prolong median overall survival and improve quality of life compared to the best supportive care alone.Recent years,with the appearance of various new agents,chemotherapy remains continuous improvement.As a result,response rate and overall survival of advanced gastric cancers were further improved.Meanwhile,with a greater understanding of the molecular biology of gastric cancer,molecular biological targeted therapies that target human epidermal growth factor receptor 2 (HER-2),endothelial growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) become the focus of the comprehensive treatment.Chemotherapy combined targeted therapy have shown great benefit and perspective in treatment of advanced gastric cancer,but their usage should be further modified and optimized in clinical trials and practices.
